UK markets closed

Biotest Aktiengesellschaft (0N6Z.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
43.00+0.10 (+0.23%)
At close: 12:23PM GMT
Full screen
Previous close42.90
Open0.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Volume0
Avg. volumeN/A
Market cap15.485M
Beta (5Y monthly)0.27
PE ratio (TTM)N/A
EPS (TTM)-1.37
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Biotest AG: First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation

    EQS-News: Biotest AG / Key word(s): StudyBiotest AG: First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation 24.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation High medical need due to severe cytomegalovirus (CMV) infections and resulting mortality after organ transplantation Study will provide data to opt

  • EQS Group

    Biotest AG: Biotest receives 'Innovation Champion of Sustainability' award

    EQS-News: Biotest AG / Key word(s): MiscellaneousBiotest AG: Biotest receives 'Innovation Champion of Sustainability' award 19.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest receives "Innovation Champion of Sustainability" award Biotest achieves very good 5th place in sustainability analysis by F.A.Z.-Institute With its GoFuture sustainability initiative, Biotest aims to grow in line with social and ecological requirements. Dr

  • EQS Group

    Biotest AG: Biotest treats first COVID-19 patients with trimodulin in TRICOVID phase III trial

    EQS-News: Biotest AG / Key word(s): StudyBiotest AG: Biotest treats first COVID-19 patients with trimodulin in TRICOVID phase III trial 10.01.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.PRESS RELEASE Biotest treats first COVID-19 patients with trimodulin in TRICOVID phase III trial Trimodulin is a worldwide unique, innovative human plasma protein preparation in advanced development Significant reduction in clinical deterioration and mortality expect